Business Wire

Vista Equity Partners Launches VistaOne to Expand Access to Private Software Investments

8.5.2025 09:00:00 CEST | Business Wire | Press release

Share

VistaOne is an evergreen investment vehicle providing direct and continuous access to the full suite of Vista’s private equity strategiesVistaOne offers fully drawn exposure to direct deals with one layer of fees and quarterly liquidity through a single, efficient access pointVistaOne is one of the first specialist-driven software and technology evergreen private equity products available to the private wealth market

Vista Equity Partners (“Vista”), a global technology investor that specializes in enterprise software, today announced the launch of VistaOne (Lux) (“VistaOne” or the “Fund”), an open-ended investment vehicle that provides eligible non-US individual investors access to Vista’s private equity platform in a single, scaled solution.

The software sector has a projected 2027 total addressable market of $59 trillion and a growth rate of approximately 17%, making it the largest and fastest growing in the global economy.1 Yet approximately 96% of software companies are privately held and therefore inaccessible to most individual investors.2 VistaOne is one of the first software-specific evergreen private equity funds available to the private wealth market.

Founded in 2000, Vista is an operationally focused investor that pioneered a proprietary and systematic approach to value creation developed and refined over the course of 25 years and 600+ transactions. Enterprise software touches almost every sector of the global economy, covering a wide range of vertical markets and end-users, and Vista currently manages a diversified portfolio of more than 90 companies providing mission-critical software solutions to 500+ million users around the world.

VistaOne is designed to offer fully drawn exposure to direct Vista deals with one layer of fees, featuring quarterly liquidity (subject to certain conditions) and low investment minimums compared to traditional private market investment strategies. With a single commitment, eligible investors gain access to a balanced portfolio across the lifecycle of large-, mid- and small-cap private software companies through Vista’s Flagship, Foundation and Endeavor private equity strategies.

“The launch of VistaOne is another significant step forward in Vista’s efforts to expand access to private software investments by providing a compelling offering for non-US investors to diversify their portfolios and broaden exposure to a generational opportunity in Generative AI,” said David Breach, Co-CEO of VistaOne and President, Chief Operating Officer of Vista Equity Partners.

VistaOne is managed by a dedicated team of investment and operations professionals at Vista who bring decades of software and operational expertise, as well as experienced private wealth sales and client service experts who work directly with wealth managers to help their clients access the untapped opportunity in enterprise software. The Fund is available to wealth managers in Vista’s immediate network and other eligible non-US investors seeking to diversify their portfolios in private equity with a software specialist.

“VistaOne provides a streamlined and efficient evergreen solution for investors seeking to increase their allocation to some of the world’s most innovative, high-growth software companies, and do so alongside one of the largest and most experienced software investors,” said Dan Parant, Co-President of VistaOne and Managing Director, Global Head of Private Wealth Solutions at Vista Equity Partners. “We are excited to offer this differentiated vehicle to the non-US private wealth market.”

For more information about VistaOne and how to invest, please visit Vista’s Private Wealth Solutions website.

Advisors

S64, a leading global alternatives fintech and solutions partner to the wealth management industry, supported Vista in the development and launch of the Fund and will be the Platform Operator. Simpson Thacher & Bartlett LLP, a global law firm that advises many of the world’s leading and most innovative companies, served as legal counsel to Vista.

About Vista Equity Partners

Vista is a global technology investor that specializes in enterprise software. Vista’s private market strategies seek to deliver differentiated returns through a proprietary and systematic approach to value creation developed and refined over the course of 25 years and 600+ transactions. Today, Vista manages a diversified portfolio of software companies that provide mission-critical solutions to millions of customers around the world. As of September 30, 2024, Vista had more than $100 billion in assets under management. Further information is available at vistaequitypartners.com. Follow Vista on LinkedIn, @Vista Equity Partners, and on X, @Vista_Equity.

____________________________________ 

1 Gartner, proprietary research as of 09/2024

2 Gartner, proprietary research as of 09/2024

View source version on businesswire.com: https://www.businesswire.com/news/home/20250507768422/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release

Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye